Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243243 · ClinicalTrials.gov registry record · Phase 3
Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
A Phase 3 study of Burns, sponsored by United States Army Institute of Surgical Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00243243 is a Phase 3 study of Burns that has completed, run by United States Army Institute of Surgical Research. The registered enrollment target is 20 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00243243, a Phase 3 study of Burns, has completed, sponsored by United States Army Institute of Surgical Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to see if a medication (Recombinant Coagulation Factor VIIa or NovoSeven), normally used to stop bleeding in persons with a bleeding disorder, will lower the amount of blood lost during burn surgery.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Recombinant Factor VIIa
Study Locations (1)
Texas
- United States Army Institute of Surgical Research - Fort Sam Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00243243
The ClinicalTrials.gov registry entry for NCT00243243 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 36 other Burns trials with a reported enrollment target (76% lower). The listed sponsor is United States Army Institute of Surgical Research, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Burns appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00243243 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00243243 about?
NCT00243243 is a clinical study titled "Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn". The purpose of the study is to see if a medication (Recombinant Coagulation Factor VIIa or NovoSeven), normally used to stop bleeding in persons with a bleeding disorder, will lower the amount of blood lost during burn surgery.
What is the current status of trial NCT00243243?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2006-01. Estimated completion is 2011-07.
What conditions does trial NCT00243243 study?
This clinical trial studies the following conditions: Burns.
What interventions are being tested in trial NCT00243243?
The interventions under investigation include: Placebo (DRUG), Recombinant Factor VIIa (DRUG).
Who is sponsoring clinical trial NCT00243243?
This trial is sponsored by United States Army Institute of Surgical Research, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00243243 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
COMPLETED · Phase 3
-
StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects
COMPLETED · Phase 3
-
Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery
COMPLETED · Phase 3
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
RECRUITING · Phase 4
-
Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.